Neural pathway · basal ganglia

Basal Ganglia · integrated notes

Motor control · disinhibition · direct & indirect pathways · disorders

🔬 General framework

The basal ganglia are a set of interconnected subcortical nuclei that modulate voluntary movement. They do not directly project to spinal cord motor neurons; instead, they influence the motor cortex via the thalamus. The main nuclei include the striatum (caudate + putamen), globus pallidus (external and internal segments), substantia nigra, and subthalamic nucleus. Two parallel, antagonistic circuits—direct and indirect—control the net excitation of the motor cortex.

Core principle: Both pathways use disinhibition (inhibitory neurons inhibit other inhibitory neurons) to ultimately excite or suppress cortical output. All connections are ipsilateral; the corticospinal tract crosses contralaterally, so unilateral basal ganglia lesions cause contralateral motor signs.

⚡ Direct pathway (promotes movement)

Cortical excitatory input → striatum (GABAergic medium spiny neurons) → inhibit the internal globus pallidus (GPi) → GPi normally inhibits the thalamus (VL) → reduced GPi inhibition → thalamus excites motor cortex → increased cortical drive and facilitation of movement.

Cortex ➜ Striatum (GABA) ➜ GPi (GABA) ➜ Thalamus (VL) ➜ Motor cortex ↑
Net effect: cortical excitation ↑ → movement initiation and execution.

⛔ Indirect pathway (suppresses movement)

Cortical input → striatum (GABA) → inhibits the external globus pallidus (GPe) → disinhibition of the subthalamic nucleus (STN) → STN (glutamatergic) excites GPi → GPi inhibits thalamus → reduced cortical excitation and suppression of unwanted movements.

Cortex ➜ Striatum (GABA) ➜ GPe (GABA) ➜ STN (Glutamate) ➜ GPi (GABA) ➜ Thalamus ↓
Net effect: cortical inhibition → suppression of involuntary or excessive movements.

🧪 Dopamine & Acetylcholine modulation

Dopamine (from substantia nigra)

  • D1 receptors on striatum → excite direct pathway (enhances movement).
  • D2 receptors → inhibit indirect pathway (also enhances movement by disinhibition).
  • Net effect: promotes voluntary movement.

Acetylcholine (striatal interneurons)

  • Activates the indirect pathway → suppresses movement.
  • Balance between dopamine and ACh is critical; in Parkinson disease, dopamine is lost, leading to relative ACh excess and hypokinesia.

🧠 Disorders of the basal ganglia

Dysfunction typically presents as dyskinesias (involuntary movements) or hypokinesia. The balance between direct and indirect pathways determines the phenotype.

  • Hypokinetic (reduced movement): Parkinson disease (direct pathway underactive).
  • Hyperkinetic (excess movement): Huntington disease, hemiballismus, Tourette, dystonia (indirect pathway underactive).

🧩 Parkinson disease

Hypokinetic Degeneration of dopaminergic neurons in the substantia nigra pars compacta. Loss of dopamine → direct pathway weakened, indirect pathway overactive → reduced cortical excitation.

  • Clinical: bradykinesia, cogwheel rigidity, resting pill-rolling tremor, shuffling gait, stooped posture, masked face, depression, dementia.
  • Pathology: Lewy bodies (α-synuclein aggregates) in surviving neurons.
  • Treatment: L-DOPA (crosses BBB), carbidopa (prevents peripheral breakdown), anticholinergics (to counter ACh excess), MAO-B inhibitors, amantadine.
  • Drug side effects: dyskinesias (with prolonged L-DOPA), hallucinations, orthostatic hypotension.
USMLE pearl: Parkinson’s tremor is resting and "pill-rolling"; intention tremor (cerebellar) is absent.

🧬 Huntington disease

Hyperkinetic Autosomal dominant; CAG trinucleotide repeat expansion on chromosome 4 (huntingtin gene). Degeneration of GABAergic neurons in the striatum (especially caudate) → loss of indirect pathway inhibition → excessive cortical excitation.

  • Clinical: chorea (rapid, random, dance-like), athetosis (slow writhing), personality changes, dementia. Onset 20–40 years.
  • Anticipation (earlier onset in successive generations) and genomic imprinting.
  • Imaging: atrophy of caudate head → dilated lateral ventricles.
  • Treatment: antipsychotics (e.g., haloperidol), benzodiazepines, anticonvulsants for chorea.
Note: Huntington is a trinucleotide repeat disease with autosomal dominant inheritance.

🪙 Wilson disease (hepatolenticular degeneration)

Hyperkinetic Autosomal recessive defect in copper transport (ATP7B mutation). Copper accumulates in liver, brain (basal ganglia), and cornea.

  • Clinical: tremor (wing-beating), parkinsonism, chorea, dystonia, psychiatric symptoms, hepatic cirrhosis, fatty liver.
  • Kayser-Fleischer rings (copper deposits in Descemet membrane) – pathognomonic.
  • Treatment: penicillamine (chelator), zinc acetate (blocks copper absorption), trientine.

💥 Hemiballismus

Lesion of the subthalamic nucleus (contralateral to the abnormal limb) → loss of excitatory input to GPi → reduced inhibition of thalamus → cortical overactivity. Causes wild, flinging movements of the contralateral arm and leg. Most commonly due to hypertensive hemorrhagic stroke.

🗣️ Tourette syndrome

Childhood-onset neurodevelopmental disorder with motor and vocal tics (snorting, sniffing, coprolalia). Often comorbid with OCD and ADHD. Treatment: antipsychotics (haloperidol, pimozide) and behavioral therapy.

💡 Clinical pearls & high-yield facts

  • Parkinson vs. Huntington: Parkinson = hypokinetic + resting tremor; Huntington = hyperkinetic + chorea.
  • Subthalamic nucleus lesions → hemiballismus (wild contralateral flinging).
  • Dopamine drives the direct pathway (D1) and inhibits the indirect pathway (D2).
  • Acetylcholine drives the indirect pathway → anticholinergics help Parkinson.
  • All basal ganglia connections are ipsilateral; unilateral lesions cause contralateral motor signs.
  • Kayser-Fleischer rings + hepatic disease + movement disorder = Wilson disease.
Mnemonics (original): "Direct = Go" (D for Direct, Dopamine, and Go). "Indirect = Stop" (Indirect suppresses).

📌 Drug mechanisms

  • L-DOPA – dopamine precursor; crosses BBB; combined with carbidopa to inhibit peripheral decarboxylase.
  • Anticholinergics (benztropine) – reduce ACh activity in striatum, rebalancing dopamine/ACh ratio.
  • MAO-B inhibitors (selegiline) – reduce dopamine breakdown.
  • Amantadine – increases dopamine release and has anticholinergic effects.
  • Penicillamine – chelates copper; used in Wilson disease.

📊 Comparison: Parkinson vs. Huntington

FeatureParkinsonHuntington
InheritanceUsually sporadic (rare genetic)Autosomal dominant (chromosome 4)
PathologySubstantia nigra degeneration, Lewy bodiesStriatal GABA neuron loss, caudate atrophy
MovementHypokinetic (bradykinesia, rigidity, resting tremor)Hyperkinetic (chorea, athetosis)
TreatmentL-DOPA, anticholinergicsAntipsychotics, benzodiazepines